PharmacoEconomics & Outcomes News 804, p27 - 2 Jun 2018 Prescription drug expenditure increasing in USA Prescription drug expenditure in USA increased in 2017 and is projected to increase further in 2018, according to findings of a study published in American Journal of Health-System Pharmacy. Data from the IQVIA National Sales Perspectives database were used to assess prescription drug expenditure (costs of purchases from drug companies) in USA in 2017. Variables with a potential impact on prescription drug expenditure in hospitals and clinics in 2018, including new drug approvals and drug patent expiries, were reviewed, and prescription drug expenditure in 2018 was projected based on quantitative analyses and expert opinion. Total expenditure on prescription drugs in the US increased by 1.7% between 2016 and 2017, to 455.9 billion. Overall, the drugs with the highest expenditure were adalimumab ($17.1 billion), insulin glargine ($9.4 billion) and etanercept ($8.8 billion). Prescription expenditure decreased by 0.7% in 2017 versus 2016 in nonfederal hospitals, to $34.2 billion (primarily due to lower utilisation), but increased by 10.9% in clinics, to $70.8 billion. In 2017, the drugs with the highest expenditure in clinics were infliximab ($3.7 billion), pegfilgrastim (3.2 billion) and rituximab ($2.8 billion), while the drugs with the highest expenditure in nonfederal hospitals were rituximab, infliximab, alteplase, immune globulin and natalizumab. Total prescription drug expenditure in 2018 was projected to increase by between 3% and 5% overall, between 11% and 13.0% in clinics, and up to 2% in hospitals. "Health-system pharmacy leaders should carefully examine their own local drug utilization patterns to determine their own organization’s anticipated spending in 2018," said the authors. Schumock GT, et al. National trends in prescription drug expenditures and projections for 2018. American Journal of Health-System Pharmacy : 10 May 2018. Available from: URL: http://doi.org/10.2146/ajhp180138 803321890 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera